1.Report of Two Patients with Severe Aplastic Anemia Who Showed Trilineage Hematologic Response to Low-dose Erythropoietin.
Kwang Woon SEO ; Wee Soo CHAE ; Suk Bong JEON ; Woo Jin SUNG ; Man Gi PARK ; Jong Gwang KIM ; Sang Kyun SOHN ; Kyu Bo LEE
Korean Journal of Hematology 2002;37(4):282-286
Aplastic anemia is characterized by multilineage bone marrow failure resulting in pancytopenia. There is no effective therapy for patients with severe aplastic anemia who were refractory to immunosuppresive therapy including antithymocyte globulin (ATG) or relapsed after allogeneic bone marrow transplantation. We report hereby that two patients with severe aplastic anemia who were relapsed after immu-nosuppresive therapy with ATG and cyclosporine A were successfully treated with low dose erythropoietin. Observed trilineage hematologic response was dependent on low dose erythropoietin therapy.
Anemia, Aplastic*
;
Antilymphocyte Serum
;
Bone Marrow
;
Bone Marrow Transplantation
;
Cyclosporine
;
Erythropoietin*
;
Humans
;
Pancytopenia
2.Prevalence of Diabetes Mellitus and Prediabetes in Dalseong-gun, Daegu City, Korea.
Jung Eun LEE ; Sung Chang JUNG ; Gui Hwa JUNG ; Sung Woo HA ; Bo Wan KIM ; Shung Chull CHAE ; Wee Hyun PARK ; Ji Sun LIM ; Jin Hoon YANG ; Sin KAM ; Byung Yeol CHUN ; Jong Yeon KIM ; Jung Jeung LEE ; Kyeong Soo LEE ; Moon Young AHN ; Young Ae KIM ; Jung Guk KIM
Diabetes & Metabolism Journal 2011;35(3):255-263
BACKGROUND: The aim of the present study was to determine the population-based prevalence of diabetes mellitus (DM) and prediabetes in a rural district of Daegu City, Korea. METHODS: Between August and November 2003, a community-based health survey of adults aged 20 years and older was performed in the rural district of Dalseong-gun in Daegu City. A total of 1,806 of all eligible individuals agreed to participate. Fasting plasma glucose was measured in all participants. Two hour oral glucose tolerance was measured in the 1,773 participants for whom there was neither an established diagnosis of DM nor evidence of DM according to fasting glucose levels. The prevalence of DM and prediabetes was determined according to the 2003 criteria of the American Diabetes Association. Subjects with prediabetes were classified into one of three categories of glucose intolerance: isolated impaired fasting glucose (IFG); isolated impaired glucose tolerance (IGT); or combined IFG and IGT. RESULTS: The prevalence of DM was 12.2%. The highest prevalence rates were observed in subjects in their seventies. A total of 34.7% of all subjects who were assigned a diagnosis of DM in the present study had not been diagnosed previously. The prevalence of prediabetes was 22.7%. The highest prevalence rates were observed in subjects in their fifties. CONCLUSION: The present study identified prevalence rates of 12.2% for DM (age-standardized prevalence rate [ASR], 6.8%), and 22.7% for prediabetes (ASR 18.5%). These results emphasize the need for community health promotion strategies to prevent or delay the onset of DM in individuals with prediabetes.
Adult
;
Aged
;
Diabetes Mellitus
;
Fasting
;
Glucose
;
Glucose Tolerance Test
;
Health Promotion
;
Health Surveys
;
Humans
;
Korea
;
Plasma
;
Prediabetic State
;
Prevalence
3.Prognosis and Natural History of Drug-Related Bradycardia.
Jang Hoon LEE ; Hyeon Min RYU ; Myung Hwan BAE ; Yong Seop KWON ; Ju Hwan LEE ; Yongwhi PARK ; Jung Ho HEO ; Young Soo LEE ; Dong Heon YANG ; Hun Sik PARK ; Yongkeun CHO ; Shung Chull CHAE ; Yoon Nyun KIM ; Jae Eun JUN ; Wee Hyun PARK
Korean Circulation Journal 2009;39(9):367-371
BACKGROUND AND OBJECTIVES: The prognosis and natural history of bradycardia related to drugs such as beta-blockers and non-dihydropyridine calcium channel blockers are not well known. SUBJECTS AND METHODS: We retrospectively analyzed 38 consecutive patients (age 69+/-11, 21 women) with drug-related bradycardia (DRB) between March 2005 and September 2007. A drug-associated etiology for the bradycardia was established based on the medical history and patient response to drug discontinuation. The mean follow-up duration was 18+/-8 months. RESULTS: The initial electrocardiogram (ECG) showed sinus bradycardia (heart rate < or =40/min) in 13 patients, sinus bradycardia with junctional escape beats in 18 patients, and third-degree atrioventricular (AV) block in seven patients. Drug discontinuation was followed by resolution of bradycardia in 60% of patients (n=23). Among them, five (17.8%) patients resumed taking the culprit medication after discharge and none developed bradycardia again. Bradycardia persisted in 10 (26.3%) patients despite drug withdrawal, and a permanent pacemaker was implanted in seven of them. Third-degree AV block, QRS width, and bradycardia requiring temporary transvenous pacing were significantly associated with the bradycardia caused by drugs. CONCLUSION: Beta-blockers were the most common drugs associated with DRB. However, in one quarter of the cases the DRB was not associated with drugs; in these patients permanent pacemaker implantation should be considered.
Arrhythmias, Cardiac
;
Atrioventricular Block
;
Bradycardia
;
Calcium Channel Blockers
;
Dichlororibofuranosylbenzimidazole
;
Electrocardiography
;
Follow-Up Studies
;
Humans
;
Natural History
;
Prognosis
;
Retrospective Studies
;
United Nations
4.Small Animal PET Imaging with 124IFIAU for Herpes Simplex Virus Type 1 Thymidine Kinase Gene Expression in a Hepatoma Model.
Min Jeong CHAE ; Tae Sup LEE ; June Youp KIM ; Gwang Sun WOO ; Wee Sup JUMG ; Kwon Soo CHUN ; Jae Hong KIM ; Ji Sup LEE ; Jin Sook RYU ; Gi Jeong CHEON ; Chang Woon CHOI ; Sang Moo LIM
Nuclear Medicine and Molecular Imaging 2008;42(3):235-234
PURPOSE: The HSV1-tk gene has been extensively studied as a type of reporter gene. In hepatocellular carcinoma (HCC), only a small proportion of patients are eligible for surgical resection and there is limitation in palliative options. Therefore, there is a need for the develoopement of new treatment modalities and gene therapy is a leading candidate. In the present study, we investigated the usefulness of substrate, 2'-fluoro-2'-deoxy-1-beta-D-arabino-furanosyl-5-[124/125I]iodo- uracil ([124/125I]FIAU) as a non-invasive imaging agent for HSV1-tk gene therapy in hepatoma model using small animal PET. MATERIAL AND METHODS: With the Morris hepatoma MCA cell line and MCA-tk cell line which was transduced with the HSV1-tk gene, in vitro uptake and correlation study between [125I]FIAU uptake according to increasing numeric count of percentage of MCA-tk cell were performed. The biodistribution data and small animal PET images with [124I]FIAU were obtained with Balb/c-nude mice bearing both MCA and MCA-tk tumors. RESULTS: Specific accumulation of [125I]FIAU was observed in MCA-tk cells but uptake was low in MCA cells. Uptake in MCA-tk cells was 15 times higher than that of MCA cells at 480 min. [125I]FIAU uptake was linearly correlated (R2=0.964, p=0.01) with increasing percentage of MCA-tk numeric cell count. Biodistribution results showed that [125I]FIAU was mainly excreted via the renal system in the early phase. Ratios of MCA-tk tumor to blood acting were 10, 41, and 641 at 1 h, 4 h, and 24 h post-injection, respectively. The maximum ratio of MCA-tk to MCA tumor was 192.7 at 24 h. Ratios of MCA-tk tumor to liver were 13.8, 66.8, and 588.3 at 1 h, 4 h, and 24 h, respectively. On small aninal PET, [124I]FIAU accumulated in substantial higher levels in MCA-tk tumor and liver than MCA tumor. CONCLUSION: FIAU shows selective accumulation to HSV1-tk expressing hepatoma cell tumors with minimal uptake in normal liver. Therefore, radiolabelled FIAU is expected to be a useful substrate for non-invasive imaging of HSV1-tk gene therapy and therapeutic response monitoring of HCC.
Animals
;
Arabinofuranosyluracil
;
Carcinoma, Hepatocellular
;
Cell Count
;
Cell Line
;
Genes, Reporter
;
Genetic Therapy
;
Herpes Simplex
;
Herpesvirus 1, Human
;
Humans
;
Liver
;
Liver Neoplasms, Experimental
;
Methylmethacrylates
;
Mice
;
Polystyrenes
;
Simplexvirus
;
Statistics as Topic
;
Uracil
;
Ursidae
5.Incidence of Hypertension in Korea: 5-Year Follow-up Study.
Jang Hoon LEE ; Dong Heon YANG ; Hun Sik PARK ; Yongkeun CHO ; Jae Eun JUN ; Wee Hyun PARK ; Byung Yeol CHUN ; Ji Yeon SHIN ; Dong Hoon SHIN ; Kyeong Soo LEE ; Kee Sik KIM ; Kwon Bae KIM ; Young Jo KIM ; Shung Chull CHAE
Journal of Korean Medical Science 2011;26(10):1286-1292
Limited data are available about the incidence of hypertension over the 5-yr in non-hypertensive subjects. The study subjects were 1,806 subjects enrolled in a rural area of Daegu, Korea for a cohort study from August to November 2003. Of them, 1,287 (71.3%) individuals had another examination 5 yr later. To estimate the incidence of hypertension, 730 non-hypertensive individuals (265 males; mean age = 56.6 +/- 11.1 yr-old) at baseline examination were analyzed in this study. Hypertension was defined as either a new diagnosis of hypertension or self-reports of newly initiated antihypertensive treatment; prehypertension was if the systolic blood pressure was 120-139 mmHg and/or diastolic blood pressure was 80-89 mmHg. During the 5-yr follow-up, 195 (26.7%) non-hypertensive individuals developed incident hypertension. The age-adjusted 5-yr incidence rates of hypertension were 22.9% (95% confidence interval [CI] = 19.9-29.0) in overall subjects, 22.2% (95% CI = 17.2-27.2) in men, and 24.3% (95% CI = 20.4-28.2) in women. The incidence rates of hypertension significantly increased with age. In the multivariate analysis, prehypertension (Odds ratio [OR] 2.25; P < 0.001) and older age (OR 2.26; P = 0.010) were independent predictors for incident hypertension. In this rapidly aging society, population-based preventive approach to decrease blood pressure, particularly in subjects with prehypertension, is needed to reduce hypertension.
Adult
;
Age Factors
;
Aged
;
Antihypertensive Agents/administration & dosage/*therapeutic use
;
*Blood Pressure
;
Blood Pressure Determination
;
Body Weights and Measures
;
Cohort Studies
;
Female
;
Follow-Up Studies
;
Humans
;
Hypertension/diagnosis/drug therapy/*epidemiology/physiopathology
;
Incidence
;
Male
;
Middle Aged
;
Questionnaires
;
Republic of Korea/epidemiology
;
Risk Factors
6.Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.
Sollip KIM ; Yeo Min YUN ; Hyo Jin CHAE ; Hyun Jung CHO ; Misuk JI ; In Suk KIM ; Kyung A WEE ; Woochang LEE ; Sang Hoon SONG ; Hye In WOO ; Soo Youn LEE ; Sail CHUN
Annals of Laboratory Medicine 2017;37(2):180-193
Pharmacogenetic testing for clinical applications is steadily increasing. Correct and adequate use of pharmacogenetic tests is important to reduce unnecessary medical costs and adverse patient outcomes. This document contains recommended pharmacogenetic testing guidelines for clinical application, interpretation, and result reporting through a literature review and evidence-based expert opinions for the clinical pharmacogenetic testing covered by public medical insurance in Korea. This document aims to improve the utility of pharmacogenetic testing in routine clinical settings.
Anticoagulants/therapeutic use
;
Antidepressive Agents/therapeutic use
;
Antimetabolites, Antineoplastic/therapeutic use
;
Antitubercular Agents/therapeutic use
;
Arylamine N-Acetyltransferase/genetics
;
Coronary Artery Disease/drug therapy/genetics
;
Cytochrome P-450 CYP2C19/genetics
;
Cytochrome P-450 CYP2C9/genetics
;
Cytochrome P-450 CYP2D6/genetics
;
Depressive Disorder/drug therapy/genetics
;
Genotype
;
Isoniazid/therapeutic use
;
Laboratories, Hospital/standards
;
Methyltransferases/genetics
;
Pharmacogenomic Testing/*methods/standards
;
Platelet Aggregation Inhibitors/therapeutic use
;
Pulmonary Embolism/drug therapy/genetics
;
Ticlopidine/analogs & derivatives/therapeutic use
;
Tuberculosis/drug therapy/genetics
;
Vitamin K Epoxide Reductases/genetics
;
Warfarin/therapeutic use
7.The Korean Society for Neuro-Oncology (KSNO) Guideline for Glioblastomas: Version 2018.01
Young Zoon KIM ; Chae Yong KIM ; Jaejoon LIM ; Kyoung Su SUNG ; Jihae LEE ; Hyuk Jin OH ; Seok Gu KANG ; Shin Hyuk KANG ; Doo Sik KONG ; Sung Hwan KIM ; Se Hyuk KIM ; Se Hoon KIM ; Yu Jung KIM ; Eui Hyun KIM ; In Ah KIM ; Ho Sung KIM ; Tae Hoon ROH ; Jae Sung PARK ; Hyun Jin PARK ; Sang Woo SONG ; Seung Ho YANG ; Wan Soo YOON ; Hong In YOON ; Soon Tae LEE ; Sea Won LEE ; Youn Soo LEE ; Chan Woo WEE ; Jong Hee CHANG ; Tae Young JUNG ; Hye Lim JUNG ; Jae Ho CHO ; Seung Hong CHOI ; Hyoung Soo CHOI ; Je Beom HONG ; Do Hoon LIM ; Dong Sup CHUNG ;
Brain Tumor Research and Treatment 2019;7(1):1-9
BACKGROUND: There has been no practical guidelines for the management of patients with central nervous system (CNS) tumors in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, started to prepare guidelines for CNS tumors from February 2018. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL using specific and sensitive keywords as well as combinations of keywords. RESULTS: First, the maximal safe resection if feasible is recommended. After the diagnosis of a glioblastoma with neurosurgical intervention, patients aged ≤70 years with good performance should be treated by concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide chemotherapy (Stupp's protocol) or standard brain radiotherapy alone. However, those with poor performance should be treated by hypofractionated brain radiotherapy (preferred)±concurrent or adjuvant temozolomide, temozolomide alone (Level III), or supportive treatment. Alternatively, patients aged >70 years with good performance should be treated by hypofractionated brain radiotherapy+concurrent and adjuvant temozolomide or Stupp's protocol or hypofractionated brain radiotherapy alone, while those with poor performance should be treated by hypofractionated brain radiotherapy alone or temozolomide chemotherapy if the patient has methylated MGMT gene promoter (Level III), or supportive treatment. CONCLUSION: The KSNO's guideline recommends that glioblastomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to the individual comprehensive condition of the patient.
Brain
;
Central Nervous System
;
Chemoradiotherapy
;
Diagnosis
;
Drug Therapy
;
Glioblastoma
;
Humans
;
Korea
;
Radiotherapy
8.The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01
Young Zoon KIM ; Chae Yong KIM ; Chan Woo WEE ; Tae Hoon ROH ; Je Beom HONG ; Hyuk Jin OH ; Seok Gu KANG ; Shin Hyuk KANG ; Doo Sik KONG ; Sung Hwan KIM ; Se Hyuk KIM ; Se Hoon KIM ; Yu Jung KIM ; Eui Hyun KIM ; In Ah KIM ; Ho Sung KIM ; Jae Sung PARK ; Hyun Jin PARK ; Sang Woo SONG ; Kyoung Su SUNG ; Seung Ho YANG ; Wan Soo YOON ; Hong In YOON ; Jihae LEE ; Soon Tae LEE ; Sea Won LEE ; Youn Soo LEE ; Jaejoon LIM ; Jong Hee CHANG ; Tae Young JUNG ; Hye Lim JUNG ; Jae Ho CHO ; Seung Hong CHOI ; Hyoung Soo CHOI ; Do Hoon LIM ; Dong Sup CHUNG ;
Brain Tumor Research and Treatment 2019;7(2):74-84
BACKGROUND: There was no practical guideline for the management of patients with central nervous system tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has developed the guideline for glioblastoma. Subsequently, the KSNO guideline for World Health Organization (WHO) grade II cerebral glioma in adults is established. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searching PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords regarding diffuse astrocytoma and oligodendroglioma of brain in adults. RESULTS: Whenever radiological feature suggests lower grade glioma, the maximal safe resection if feasible is recommended globally. After molecular and histological examinations, patients with diffuse astrocytoma, isocitrate dehydrogenase (IDH)-wildtype without molecular feature of glioblastoma should be primarily treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy (Level III) while those with molecular feature of glioblastoma should be treated following the protocol for glioblastomas. In terms of patients with diffuse astrocytoma, IDH-mutant and oligodendroglioma (IDH-mutant and 1p19q codeletion), standard brain radiotherapy and adjuvant PCV (procarbazine+lomustine+vincristine) combination chemotherapy should be considered primarily for the high-risk group while observation with regular follow up should be considered for the low-risk group. CONCLUSION: The KSNO's guideline recommends that WHO grade II gliomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors and clinical characteristics of patients.
Adult
;
Astrocytoma
;
Brain
;
Central Nervous System
;
Drug Therapy
;
Drug Therapy, Combination
;
Follow-Up Studies
;
Glioblastoma
;
Glioma
;
Humans
;
Isocitrate Dehydrogenase
;
Korea
;
Oligodendroglioma
;
Radiotherapy
;
World Health Organization
9.The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01
Young Zoon KIM ; Chae Yong KIM ; Jaejoon LIM ; Kyoung Su SUNG ; Jihae LEE ; Hyuk Jin OH ; Seok Gu KANG ; Shin Hyuk KANG ; Doo Sik KONG ; Sung Hwan KIM ; Se Hyuk KIM ; Se Hoon KIM ; Yu Jung KIM ; Eui Hyun KIM ; In Ah KIM ; Ho Sung KIM ; Tae Hoon ROH ; Jae Sung PARK ; Hyun Jin PARK ; Sang Woo SONG ; Seung Ho YANG ; Wan Soo YOON ; Hong In YOON ; Soon Tae LEE ; Sea Won LEE ; Youn Soo LEE ; Chan Woo WEE ; Jong Hee CHANG ; Tae Young JUNG ; Hye Lim JUNG ; Jae Ho CHO ; Seung Hong CHOI ; Hyoung Soo CHOI ; Je Beom HONG ; Do Hoon LIM ; Dong Sup CHUNG ;
Brain Tumor Research and Treatment 2019;7(2):63-73
BACKGROUND: There was no practical guideline for the management of patients with central nervous system tumor in Korea in the past. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, developed the guideline for glioblastoma successfully and published it in Brain Tumor Research and Treatment, the official journal of KSNO, in April 2019. Recently, the KSNO guideline for World Health Organization (WHO) grade III cerebral glioma in adults has been established. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searches in PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords. Scope of the disease was confined to cerebral anaplastic astrocytoma and oligodendroglioma in adults. RESULTS: Whenever radiological feature suggests high grade glioma, maximal safe resection if feasible is globally recommended. After molecular and histological examinations, patients with anaplastic astrocytoma, isocitrate dehydrogenase (IDH)-mutant should be primary treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy whereas those with anaplastic astrocytoma, NOS, and anaplastic astrocytoma, IDH-wildtype should be treated following the protocol for glioblastomas. In terms of anaplastic oligodendroglioma, IDH-mutant and 1p19q-codeletion, and anaplastic oligodendroglioma, NOS should be primary treated by standard brain radiotherapy and neoadjuvant or adjuvant PCV (procarbazine, lomustine, and vincristine) combination chemotherapy. CONCLUSION: The KSNO's guideline recommends that WHO grade III cerebral glioma of adults should be treated by maximal safe resection if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors.
Adult
;
Astrocytoma
;
Brain
;
Brain Neoplasms
;
Central Nervous System
;
Drug Therapy
;
Drug Therapy, Combination
;
Glioblastoma
;
Glioma
;
Humans
;
Isocitrate Dehydrogenase
;
Korea
;
Lomustine
;
Oligodendroglioma
;
Radiotherapy
;
World Health Organization